Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement

Seraxis Holdings to Merge with Sernova Biotherapeutics

September 8, 2026

Biotechnology

Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc. in a merger of equals, with shareholders of each company expected to own approximately 50% of the combined company. The combined business is expected to operate as BetaNova Biotherapeutics, with the transaction subject to shareholder, court, and regulatory approvals and expected to close in November 2026.

Talawar Therapeutics to Go Public via Business Combination with JATT II Acquisition Corp

June 29, 2026

Biotechnology

Talawar Therapeutics entered into a definitive business combination agreement with JATT II Acquisition Corp to create a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases. The transaction is expected to close in the second half of 2026 and includes an oversubscribed $225 million PIPE alongside $60 million held in JATT II’s trust account (assuming no redemptions).

Boundless Affiliates with Merakey USA to Create a National Human Services Model

June 25, 2026

Healthcare Services

Boundless and Merakey USA announced a strategic affiliation to create a shared national framework for delivering “whole-person, whole-life care” for people with autism, mental health conditions, substance use disorders, and intellectual/developmental disabilities. Under the affiliation, Boundless will continue operating under its established name while connecting to Merakey’s broader platform and capabilities.

Rallybio Corporation to Acquire Avenzo Therapeutics in $215M Financing Deal

June 2, 2026

Biotechnology

Rallybio Corporation entered into a definitive merger agreement to acquire Avenzo Therapeutics, with the combined company expected to operate as Avenzo Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVZO. The transaction includes a concurrent, oversubscribed $215 million private placement with participation from healthcare institutional investors and mutual funds, and is expected to close in Q4 2026 subject to customary conditions.

Woven Health Collective Acquires Boundless Life Sciences Group

July 9, 2025

Healthcare Services

Woven Health Collective has acquired Boundless Life Sciences Group, integrating Boundless' digital-first creative marketing and AI capabilities into Woven's biopharmaceutical marketing and scientific communications platform. The deal expands Woven's commercialization services and digital/creative offerings to better serve life sciences clients across the product lifecycle.

SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

October 20, 2021

Biotechnology

SAB Biotherapeutics entered into a definitive business combination/merger agreement with Big Cypress Acquisition Corp. (a SPAC), with the combined company to operate as SAB Biotherapeutics and be listed on Nasdaq. Big Cypress stockholders approved the deal, and the transaction was expected to close on or about October 22, 2021, subject to customary conditions.